RxDoctor Payments Data

Amul Bhalodi, MD

Urology · Lexington, KYNPI 1750644407

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations.

$5,336in general payments, 2019–2025

Across 170 payments — averaging $31.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$874
  • Sumitomo Pharma America, Inc.$634
  • Axonics, Inc.$570
  • Teleflex LLC$524
  • Procept Biorobotics Corporation$433
  • 180 Medical, Inc.$390
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,25198%
  • Education$862%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,336 in reported general payments places this provider in the 70th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$131,292
Medicare patients
277
Services billed
1,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron58$44,148
GemtesaVibegron17$16,143
Solifenacin Succinate45$3,164
Tamsulosin Hcl291$2,931
Estradiol35$1,670
Tolterodine Tartrate ErTolterodine Tartrate11$1,352
Finasteride96$878
Cefdinir62$573
Oxybutynin Chloride ErOxybutynin Chloride16$535
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$201
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim69$154
Fluconazole15$123
Oxybutynin Chloride54$120
Tramadol Hcl73$78
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$67$44,14858 claims
Sumitomo Pharma America, Inc.Gemtesa$634$16,14317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 139 urology providers in Kentucky.

Other urology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →